JIP4 is recruited by the phosphoinositide-binding protein Phafin2 to promote recycling tubules on macropinosomes.


Journal

Journal of cell science
ISSN: 1477-9137
Titre abrégé: J Cell Sci
Pays: England
ID NLM: 0052457

Informations de publication

Date de publication:
15 07 2021
Historique:
received: 29 01 2021
accepted: 27 05 2021
pubmed: 11 6 2021
medline: 13 8 2021
entrez: 10 6 2021
Statut: ppublish

Résumé

Macropinocytosis allows cells to take up extracellular material in a non-selective manner into large vesicles called macropinosomes. After internalization, macropinosomes acquire phosphatidylinositol 3-phosphate (PtdIns3P) on their limiting membrane as they mature into endosomal-like vesicles. The molecular mechanisms that underlie recycling of membranes and transmembrane proteins from these macropinosomes still need to be defined. Here, we report that JIP4 (officially known as SPAG9), a protein previously described to bind to microtubule motors, is recruited to tubulating subdomains on macropinosomes by the PtdIns3P-binding protein Phafin2 (officially known as PLEKHF2). These JIP4-positive tubulating subdomains on macropinosomes contain F-actin, the retromer recycling complex and the retromer cargo VAMP3. Disruption of the JIP4-Phafin2 interaction, deletion of Phafin2 or inhibition of PtdIns3P production by VPS34 impairs JIP4 recruitment to macropinosomes. Whereas knockout of JIP4 suppresses tubulation, its overexpression enhances tubulation from macropinosomes. JIP4-knockout cells display increased retention of macropinocytic cargo in both early and late macropinosomes. Collectively, these data identify JIP4 and Phafin2 as components of a tubular recycling pathway that operates from macropinosomes. This article has an associated First Person interview with the first author of the paper.

Identifiants

pubmed: 34109410
pii: 269048
doi: 10.1242/jcs.258495
pmc: PMC8325962
pii:
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Carrier Proteins 0
PLEKHF2 protein, human 0
Phosphatidylinositols 0
SPAG9 protein, human 0
Vesicular Transport Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2021. Published by The Company of Biologists Ltd.

Déclaration de conflit d'intérêts

Competing interests The authors declare no competing or financial interests.

Références

Traffic. 2012 Nov;13(11):1547-63
pubmed: 22816767
Mol Syst Biol. 2011 Oct 11;7:539
pubmed: 21988835
J Cell Biol. 2015 Oct 26;211(2):339-58
pubmed: 26504170
Mol Biol Cell. 2019 Jun 1;30(12):1477-1489
pubmed: 30969891
Structure. 2020 Apr 7;28(4):406-417.e6
pubmed: 32017888
Protein Sci. 2017 Apr;26(4):814-823
pubmed: 28152563
Curr Biol. 2011 Apr 12;21(7):574-9
pubmed: 21439824
J Biol Chem. 2012 Aug 17;287(34):28619-31
pubmed: 22740695
Sci Adv. 2020 Nov 11;6(46):
pubmed: 33177079
Mol Biol Cell. 2021 May 15;32(11):1094-1103
pubmed: 33788575
Mol Biol Cell. 1998 Jun;9(6):1437-48
pubmed: 9614185
Acta Crystallogr F Struct Biol Commun. 2016 Mar;72(Pt 3):198-206
pubmed: 26919523
Nat Commun. 2017 Nov 17;8(1):1580
pubmed: 29146937
Philos Trans R Soc Lond B Biol Sci. 2019 Feb 4;374(1765):20180158
pubmed: 30967007
Curr Biol. 2009 Feb 10;19(3):184-95
pubmed: 19211056
Int J Mol Sci. 2009 Jun 18;10(6):2763-88
pubmed: 19582228
EMBO J. 2009 Sep 16;28(18):2835-45
pubmed: 19644450
PLoS Biol. 2011 Mar;9(3):e1000604
pubmed: 21445324
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
PLoS One. 2014 Jan 08;9(1):e79795
pubmed: 24416124
Semin Cell Dev Biol. 2014 Jul;31:40-7
pubmed: 24641888
Cell Death Differ. 2015 Aug;22(8):1260-74
pubmed: 25571974
J Cell Biol. 2002 Sep 16;158(6):1119-31
pubmed: 12221069
Structure. 2018 Nov 6;26(11):1486-1498.e6
pubmed: 30197037
Biochim Biophys Acta Biomembr. 2020 Jun 1;1862(6):183230
pubmed: 32126233
Philos Trans R Soc Lond B Biol Sci. 2019 Feb 4;374(1765):20180146
pubmed: 30967000
FEBS Lett. 2012 Jul 16;586(15):2097-105
pubmed: 22584056
Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):E5906-E5915
pubmed: 27647881
Bioinformatics. 2009 May 1;25(9):1189-91
pubmed: 19151095
Nucleic Acids Res. 2019 Jul 2;47(W1):W636-W641
pubmed: 30976793
Cold Spring Harb Perspect Biol. 2014 Feb 01;6(2):
pubmed: 24492709
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
Nat Commun. 2019 Jun 28;10(1):2850
pubmed: 31253801
Anal Chem. 2003 Feb 1;75(3):663-70
pubmed: 12585499
Annu Rev Cell Dev Biol. 2016 Oct 6;32:555-576
pubmed: 27501444
J Struct Biol. 1996 Jan-Feb;116(1):71-6
pubmed: 8742726
Sci Rep. 2019 Nov 5;9(1):16036
pubmed: 31690808
Curr Biol. 2021 May 24;31(10):2140-2154.e6
pubmed: 33765413
J Cell Sci. 2013 Mar 15;126(Pt 6):1307-16
pubmed: 23645161
Nat Chem Biol. 2014 Dec;10(12):1013-9
pubmed: 25326666

Auteurs

Kia Wee Tan (KW)

Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Montebello N-0379 Oslo, Norway.
Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Montebello 0379 Oslo, Norway.

Viola Nähse (V)

Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Montebello N-0379 Oslo, Norway.
Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Montebello 0379 Oslo, Norway.

Coen Campsteijn (C)

Department of Molecular Medicine, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, 0372 Oslo, Norway.

Andreas Brech (A)

Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Montebello N-0379 Oslo, Norway.
Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Montebello 0379 Oslo, Norway.

Kay Oliver Schink (KO)

Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Montebello N-0379 Oslo, Norway.
Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Montebello 0379 Oslo, Norway.

Harald Stenmark (H)

Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Montebello N-0379 Oslo, Norway.
Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Montebello 0379 Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH